• A 74-Year-Old Man With Waldenstrom Macroglobulinemia and Progressive Dyspnea
• A case of hyperviscosity syndrome associated with Waldenstrom macroglobulinemia treated with membrane plasma exchange without predilution
• A Copernican revolution of multigenic analysis: A retrospective study on clinical exome sequencing in unclear genetic disorders
• A Mystery in a Case: Unraveling the Complexity of Bing-Neel Syndrome
• A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
• A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia
• A Rare Case of Non-IgM Lymphoplasmacytic Lymphoma with Unusual Lack of Immunoglobulin Light Chain Production
• A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)
• A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS
• Acute Abdominal Pain as the Initial Presentation of an Acquired C1 Inhibitor Deficiency
• Advanced case of Waldenstrom macroglobulinemia complicated by acquired hemophilia A in a patient with neurofibromatosis type 1
• An advanced case of Waldenstrom's macroglobulinemia complicated by acquired hemophilia a in a patient with neurofibromatosis type 1
• An unusual presentation of lymphoplasmacytic lymphoma with isolated brachial plexus infiltration and amyloidosis
• Antineutrophil cytoplasmic antibody-negative pauci-immune glomerulonephritis in a patient with Waldenstrom macroglobulinaemia
• Asymptomatic erythematous plaques on the trunk
• Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer
• Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis
• Bilateral reversible optic neuropathy as the first sign of Waldenstrom macroglobulinema
• Bing-Neel syndrome, a rare manifestation of WM; a case report and review of literature
• Bing-Neel syndrome: A rare complication of waldenstrom macroglobulinemia
• Bing-Neel Syndrome: An Unknown GCA Mimicker
• Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenstrom Macroglobulinemia
• Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom macroglobulinemia
• Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenstrom Macroglobulinemia
• BTK Inhibitors in CLL : Second Generation Drugs and Beyond
• BTK inhibitors in CLL: second-generation drugs and beyond
• Case report: Waldenstrom macroglobulinemia with systemic amyloidosis as the main manifestation
• Circulating tumor cells in Waldenstrom macroglobulinemia
• Content validation of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin's lymphoma
• Correction to 'A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia'
• Correction: Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report
• Covalent docking-driven virtual screening of extensive small-molecule libraries against Bruton tyrosine kinase for the identification of highly selective and potent novel therapeutic candidates
• Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial
• Diagnosis and treatment understanding of Waldenstrom macroglobulinemia in China: a cross-sectional study
• Different extramedullary disease shown in chemokine receptor 4 targeted PET/CT with [ 68 Ga]Ga-pentixafor in patients with Waldenstrom macroglobulinemia and smoldering disease
• Different extramedullary disease shown in chemokine receptor 4 targeted PET/CT with [68Ga]Ga-pentixafor in patients with Waldenstrom macroglobulinemia and smoldering disease
• Dutcher bodies in a Waldenstrom Macroglobulinaemia patient
• Editor's Note: Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia
• Editor's Note: Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
• Enhancing Plasmapheresis Efficacy in Waldenstrom Macroglobulinemia: Overcoming Circuit Clotting Challenges
• Erratum to: The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia
• Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
• Ethnic diversity in presentation and outcome of Waldenstrom macroglobulinemia and IgM monoclonal gammopathy of clinical significance in the United Kingdom
• Gammopathic dermopathy: characterization of cutaneous MGUS
• Health-related quality of life in patients with Waldenstrom macroglobulinemia: results from the ASPEN trial
• Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib
• High efficacy of CD19 CAR T cells in patients with transformed Waldenstrom macroglobulinemia
• High efficacy of CD19 CAR T-cells in patients with transformed Waldenstrom macroglobulinemia
• How to manage waldenstrom's macroglobulinemia in 2024
• Ibrutinib (Imbruvica): CADTH Reimbursement Review: Therapeutic area: Waldenstrom macroglobulinemia
• Identification of robust predictors for ibrutinib response by multi-omics in MYD88 mutated Waldenstrom Macroglobulinemia
• Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenstrom macroglobulinemia
• Immunoglobulin class-switch recombination: Mechanism, regulation, and related diseases
• Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenstrom Macroglobulinemia: a monocentric experience
• In-vivo pharmacokinetic study of ibrutinib-loaded nanostructured lipid carriers in rat plasma by sensitive spectrofluorimetric method using harmonized approach of quality by design and white analytical chemistry
• Incidence and Risk of Secondary Malignancy in Patients with Waldenstrom Macroglobulinemia: A Population-Based Analysis
• Infection as a trigger of acute, transient glomerular deposition of clonal immunoglobulins
• Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis
• Inference of genomic lesions from single-cell RNAseq in myeloma improves functional intra- and inter-clonal analysis
• Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B
• Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrom macroglobulinaemia
• Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
• Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review
• Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia Diagnosed Following Recurrent Epistaxis
• Monoclonal gammopathy of renal significance: An atypical presentation of Waldenstrom's disease
• Mutational landscape in Waldenstrom macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice
• MYD88(WT)CXCR4(MUT) Waldenstrom macroglobulinemia: a case report
• Novel Approaches to Managing Patients with Relapsed and Refractory Waldenstrom Macroglobulinemia
• Optical coherence tomography angiography features in Waldenstrom macroglobulinemia patients without Hyperviscosity syndrome: A pilot prospective study
• Optimizing BTK Inhibition in Waldenstrom Macroglobulinemia
• Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial
• Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
• PlentiPlex MYD88 Waldenstrom lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation
• Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients
• Risk/benefit of BTK/venetoclax combos: the context matters!
• Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
• Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenstrom macroglobulinemia
• Serum hyperviscosity syndrome: Update 2024
• Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia
• Single-cell analysis of MYD88(L265P) and MYD88(WT) Waldenstrom macroglobulinemia patients
• Spurious dyslipidemia due to paraprotein in a patient with Waldenstrom macroglobulinemia
• ST2825, independent of MyD88, induces reactive oxygen species-dependent apoptosis in multiple myeloma cells
• Successful Implementation of Combined Treatment Methods for a Rare Recurrence of Waldenstrom Macroglobulinemia With Extramedullary Lesions
• Sudden unexpected death after initial infusion of rituximab for Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma: an autopsy case
• Sustained Response of Ibrutinib in a Patient with Waldenstrom Macroglobulinemia Presenting with Myasthenic Crisis as a Paraneoplastic Neurological Syndrome: A Case Report and Review of Literature
• The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
• The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas
• The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms
• The landscape of rare genetic variants in familial Waldenstrom macroglobulinemia
• There's life in the old dog yet: immunochemotherapy in Waldenstrom's macroglobulinemia
• Unlocking the therapeutic potential of selective CDK7 and BRD4 Inhibition against multiple myeloma cell growth
• Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report
• Uveal effusion in Waldenstrom's macroglobulinemia
• Waldenstrom macroglobulinaemia with AA amyloidosis reveals a B-cell-restricted NLRP2 variant
• Waldenstrom Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems
• Waldenstrom macroglobulinemia presenting as bilateral bloody pleural effusion: A case report
• Waldenstrom Macroglobulinemia-Associated Peripheral Neuropathy in the Brachial Plexus With Bing-Neel Syndrome Diagnosed Through Repeated Cerebrospinal Tests
• Waldenstrom macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy
• Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
• When Waldenstrom macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario